Wojciech Paslawski
Overview
Explore the profile of Wojciech Paslawski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
373
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Clark K, White A, Paslawski W, Alexander K, Peng S, Young-Pearse T, et al.
Mol Biol Cell
. 2025 Jan;
36(2):br4.
PMID: 39745872
Parkinson disease (PD) is the second most common neurodegenerative disease, characterized by both motor and cognitive features. Motor symptoms primarily involve midbrain dopaminergic neurons, while cognitive dysfunction involves cortical neurons....
2.
Kotowska M, Wenecki M, Bednarz B, Ciekot J, Paslawski W, Buhl T, et al.
Appl Microbiol Biotechnol
. 2024 Dec;
108(1):531.
PMID: 39656307
Coelimycin (CPK) producer Streptomyces coelicolor A3(2) is a well-established model for the genetic studies of bacteria from the genus Streptomyces, renowned for their ability to produce a plethora of antibiotics...
3.
Appleton E, Khosousi S, Ta M, Nalls M, Singleton A, Sturchio A, et al.
Transl Neurodegener
. 2024 Jun;
13(1):31.
PMID: 38863007
No abstract available.
4.
Khosousi S, Sturchio A, Appleton E, Paslawski W, Ta M, Nalls M, et al.
Mov Disord
. 2024 May;
39(10):1881-1885.
PMID: 38798037
Background: Recent studies identified increased cerebrospinal fluid (CSF) DOPA decarboxylase (DDC) as a promising biomarker for parkinsonian disorders, suggesting a compensation to dying dopaminergic neurons. A correlation with 123I-FP-CIT-SPECT (DaT-SPECT)...
5.
Dautan D, Paslawski W, Montejo S, Doyon D, Marangiu R, Kaplitt M, et al.
bioRxiv
. 2024 May;
PMID: 38712208
Parkinson's disease (PD) is characterized by progressive motor as well as less recognized non-motor symptoms that arise often years before motor manifestation, including sleep and gastrointestinal disturbances. Despite the heavy...
6.
Kojima R, Paslawski W, Lyu G, Arenas E, Zhang X, Svenningsson P
Int J Mol Sci
. 2024 Jan;
25(1).
PMID: 38203854
Mutations in the gene increase the risk of developing Parkinson's disease (PD). However, most carriers of mutations do not develop PD throughout their lives. The mechanisms of how mutations contribute...
7.
dorovic D, Lazarevic V, Arandelovic J, Stevanovic V, Paslawski W, Zhang X, et al.
J Affect Disord
. 2024 Jan;
349:286-296.
PMID: 38199412
Background: Early life stress is a major risk factor for later development of psychiatric disorders, including post-traumatic stress disorder (PTSD). An intricate relationship exists between various neurotransmitters (such as glutamate,...
8.
Uzuegbunam B, Li J, Paslawski W, Weber W, Svenningsson P, Agren H, et al.
Int J Mol Sci
. 2023 Nov;
24(22).
PMID: 38003637
The α-synucleinopathies are a group of neurodegenerative diseases characterized by the deposition of α-synuclein aggregates (α-syn) in the brain. Currently, there is no suitable tracer to enable a definitive early...
9.
Isolation of L1CAM-Extracellular Vesicles Reveals Signs of Insulin Resistance in Parkinson's Disease
Markaki I, Paslawski W, Ntetsika T, Engesvik L, Catrina S, Svenningsson P
Mov Disord
. 2023 Sep;
38(11):2136-2137.
PMID: 37670426
No abstract available.
10.
Paslawski W, Khosousi S, Hertz E, Markaki I, Boxer A, Svenningsson P
Transl Neurodegener
. 2023 Sep;
12(1):42.
PMID: 37667404
Background: There is a need for biomarkers to support an accurate diagnosis of Parkinson's disease (PD). Cerebrospinal fluid (CSF) has been a successful biofluid for finding neurodegenerative biomarkers, and modern...